These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16206114)

  • 21. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
    Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
    Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased plasma efavirenz concentrations in a patient receiving rifabutin.
    Hsu O; Hill CJ; Kim M; Tan B; O'Brien JG
    Am J Health Syst Pharm; 2010 Oct; 67(19):1611-4. PubMed ID: 20852162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
    Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
    J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
    Spradling P; Drociuk D; McLaughlin S; Lee LM; Peloquin CA; Gallicano K; Pozsik C; Onorato I; Castro KG; Ridzon R
    Clin Infect Dis; 2002 Nov; 35(9):1106-12. PubMed ID: 12384845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
    Brennan-Benson P; Lyus R; Harrison T; Pakianathan M; Macallan D
    AIDS; 2005 Sep; 19(14):1541-3. PubMed ID: 16135909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N; Purwantyastuti ; Instiaty ; Rusli A
    Acta Med Indones; 2016 Jan; 48(1):10-6. PubMed ID: 27241539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
    DiCenzo R; Peterson D; Cruttenden K; Morse G; Riggs G; Gelbard H; Schifitto G
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4328-31. PubMed ID: 15504860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
    Dybul M; Nies-Kraske E; Dewar R; Maldarelli F; Hallahan CW; Daucher M; Piscitelli SC; Ehler L; Weigand A; Palmer S; Metcalf JA; Davey RT; Rock Kress DM; Powers A; Beck I; Frenkel L; Baseler M; Coffin J; Fauci AS
    J Infect Dis; 2004 Jun; 189(11):1974-82. PubMed ID: 15143462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
    Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
    Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
    Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
    Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
    Bienvenu E; Swart M; Dandara C; Ashton M
    Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):439-43. PubMed ID: 19223781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.